false
0001176309
0001176309
2025-11-16
2025-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report:
(Date of earliest event reported)
November 16, 2025
Oramed Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-35813 |
|
98-0376008 |
(State or other jurisdiction
of incorporation) |
|
(Commission File No.) |
|
(IRS Employer
Identification No.) |
1185 Avenue of the Americas, Third Floor,
New York, New York 10036
(Address of principal executive offices and zip
code)
(844) 967-2633
(Registrant’s telephone number, including area
code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
| Title of each class |
|
Trading symbol |
|
Name of each exchange on which registered |
| Common Stock, par value $0.012 |
|
ORMP |
|
The Nasdaq Capital Market,
Tel Aviv Stock Exchange |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01. Entry into a Material Definitive Agreement.
On November 16, 2025, the
Board of Directors of Oramed Pharmaceuticals Inc. (the “Company”) declared a dividend of one common stock purchase right (a
“Right”) for each outstanding share of common stock, par value $0.012 per share (the “Common Stock”), of the Company.
The dividend is payable on November 27, 2025 to the stockholders of record at the close of business on November 27, 2025 (the “Record
Date”). Each Right initially entitles the registered holder to purchase from the Company one share of Common Stock at a price of
$10.00 per share of Common Stock (the “Purchase Price”), subject to adjustment. The description and terms of the Rights are
set forth in a Rights Agreement dated as of November 17, 2025, as the same may be amended from time to time (the “Rights Agreement”),
between the Company and Continental Stock Transfer & Trust Company, as Rights Agent (the “Rights Agent”).
Until the earlier to occur
of (i) 10 business days following a public announcement that a person or group of affiliated or associated persons has become an Acquiring
Person (as defined below) or (ii) 10 business days (or such later date as may be determined by action of the Board of Directors prior
to such time as any person or group of affiliated or associated persons becomes an Acquiring Person) following the commencement of, or
public announcement of an intention to make, a tender or exchange offer the consummation of which would result in any person or group
of affiliated or associated persons becoming an Acquiring Person (the earlier of such dates being called the “Distribution Date”),
the Rights will be evidenced, with respect to certificates representing Common Stock (or book entry shares of Common Stock) outstanding
as of the Record Date, by such certificates (or such book entry shares). Except in certain situations, a person or group of affiliated
or associated persons becomes an “Acquiring Person” upon acquiring beneficial ownership of 15% or more of the outstanding shares
of Common Stock. Certain synthetic interests in securities created by derivative positions – whether or not such interests are considered
to be ownership of the underlying Common Stock or are reportable for purposes of Regulation 13D of the Securities Exchange Act of 1934,
as amended – are treated as beneficial ownership of the number of shares of the Common Stock equivalent to the economic exposure
created by the derivative security, to the extent actual shares of Common Stock are directly or indirectly beneficially owned by a counterparty
to such derivative security.
The Rights Agreement provides
that, until the Distribution Date (or earlier expiration of the Rights), the Rights will be transferred with and only with the Common
Stock. Until the Distribution Date (or earlier expiration of the Rights), new Common Stock certificates issued after the Record Date upon
transfer or new issuances of Common Stock will contain a notation incorporating the Rights Agreement by reference. Until the Distribution
Date (or earlier expiration of the Rights), the surrender for transfer of any certificates for shares of Common Stock (or book entry shares
of Common Stock) outstanding as of the Record Date, even without such notation, will also constitute the transfer of the Rights associated
with the shares of Common Stock represented thereby. As soon as practicable following the Distribution Date, separate certificates evidencing
the Rights (“Right Certificates”) will be mailed to holders of record of the Common Stock as of the close of business on the
Distribution Date and such separate Right Certificates alone will evidence the Rights.
The Rights are not exercisable
until the Distribution Date. The Rights will expire three years after the date of the Rights Agreement unless the Rights are earlier redeemed
or exchanged by the Company as described below or otherwise terminated.
The Purchase Price payable,
and the number of shares of Common Stock (or cash, other assets, debt securities of the Company, or any combination thereof equivalent
in value thereto) issuable, upon exercise of the Rights is subject to adjustment from time to time to prevent dilution (i) in the event
of a stock dividend on, or a subdivision, combination or reclassification of, the Common Stock, (ii) upon the grant to holders of the
Common Stock of certain rights or warrants to subscribe for or purchase Common Stock at a price, or securities convertible into Common
Stock with a conversion price, less than the then-current market price of the Common Stock or (iii) upon the distribution to holders of
the Common Stock of evidences of indebtedness or assets (excluding regular periodic cash dividends or dividends payable in Common Stock)
or of subscription rights or warrants (other than those referred to above).
The number of outstanding
Rights is subject to adjustment in the event of a stock dividend on the Common Stock payable in shares of Common Stock or subdivisions,
consolidations or combinations of the Common Stock occurring, in any such case, prior to the Distribution Date.
In the event that any person
or group of affiliated or associated persons becomes an Acquiring Person, each holder of a Right, other than Rights beneficially owned
by the Acquiring Person (which will thereupon become void), will thereafter have the right to receive upon exercise of a Right that number
of shares of Common Stock (or cash, other assets, debt securities of the Company, or any combination thereof) having a market value of
two times the exercise price of the Right.
In the event that, after a
person or group has become an Acquiring Person, the Company is acquired in a merger or other business combination transaction or 50% or
more of its consolidated assets or earning power are sold, proper provisions will be made so that each holder of a Right (other than Rights
beneficially owned by an Acquiring Person which will have become void) will thereafter have the right to receive upon the exercise of
a Right that number of shares of common stock of the person with whom the Company has engaged in the foregoing transaction (or its parent)
that at the time of such transaction have a market value of two times the exercise price of the Right.
At any time after any person
or group becomes an Acquiring Person and prior to the earlier of one of the events described in the previous paragraph or the acquisition
by such Acquiring Person of 50% or more of the outstanding shares of Common Stock, the Board of Directors may exchange the Rights (other
than Rights owned by such Acquiring Person which will have become void), in whole or in part, for shares of Common Stock or the right
to receive shares of Common Stock (or cash, other assets, debt securities of the Company, or any combination thereof with an aggregate
value equal to such shares) at an exchange ratio of one share of Common Stock or the right to receive one share of Common Stock (or cash,
other assets, debt securities of the Company, or any combination thereof equivalent in value thereto) per Right.
With certain exceptions, no
adjustment in the Purchase Price will be required until cumulative adjustments require an adjustment of at least 1% in such Purchase Price.
No fractional shares of Common Stock will be issued, and in lieu thereof a cash payment will be made based on then current market price
of the Common Stock.
At any time prior to the time
an Acquiring Person becomes such, the Board of Directors may redeem the Rights in whole, but not in part, at a price of $0.012 per Right
(the “Redemption Price”) payable, at the option of the Company, in cash, shares of Common Stock or such other form of consideration
as the Board of Directors shall determine. The redemption of the Rights may be made effective at such time, on such basis and with such
conditions as the Board of Directors in its sole discretion may establish. Immediately upon any redemption of the Rights, the right to
exercise the Rights will terminate and the only right of the holders of Rights will be to receive the Redemption Price.
For so long as the Rights
are then redeemable, the Company may, except with respect to the Redemption Price, amend the Rights Agreement in any manner. After the
Rights are no longer redeemable, the Company may, except with respect to the Redemption Price, amend the Rights Agreement in any manner
that does not adversely affect the interests of holders of the Rights.
Until a Right is exercised
or exchanged, the holder thereof, as such, will have no rights as a stockholder of the Company, including, without limitation, the right
to vote or to receive dividends.
The form of Rights Agreement
between the Company and the Rights Agent specifying the terms of the Rights, which includes as Exhibit A the form of Rights Certificate,
and a press release issued by the Company on November 17, 2025 with respect to the dividend of the Rights, are attached hereto as Exhibits
4.1 and 99.1, respectively, and are incorporated herein by reference. The foregoing description of the Rights does not purport to be complete
and is qualified in its entirety by reference to the full text of the Rights Agreement filed as Exhibit 4.1.
Item
3.03 Material Modification to Rights of Security Holders.
The information set forth
in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 3.03 by reference.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit 4.1 |
|
Rights Agreement, dated as of November 17, 2025, between Oramed Pharmaceuticals Inc. and Continental Stock Transfer & Trust Company, as Rights Agent. |
| |
|
|
| Exhibit 99.1 |
|
Press Release dated November 17, 2025. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
ORAMED PHARMACEUTICALS INC. |
| |
|
|
|
| Date: November 17, 2025 |
By: | /s/ Nadav Kidron |
| |
|
Name: |
Nadav Kidron |
| |
|
Title: |
President and Chief
Executive Officer |
